MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces the appointment of Andrew Charles Barker as a Non-Executive Director effective immediately. Upon joining, Andrew will succeed David Baynes as Chairman of the Remuneration Committee, while David will retain the Chairmanship of the Company’s Audit Committee.
Andrew, 59, has over 30 years’ experience in senior management of technology and software businesses and in venture capital, having been involved in the early stages of internet computing with Sun Microsystems in Silicon Valley, later going on to help build Intel’s venture arm in the UK.
He is an experienced NED and investor in early-stage companies with disruptive technology. His portfolio has a med-tech focus and, in addition to his position as a Director of Intelligent Ultrasound Limited (acquired by MedaPhor on 6 October 2017, RNS number: 8775S), Andrew is the Chairman of Brainomix, a University of Oxford medical imaging spin out and a Partner of Anchard Associates LLP.
Riccardo Pigliucci, Chairman of MedaPhor, said: “I am very pleased to welcome Andrew to the Board. In addition to bringing a wealth of relevant experience, his appointment highlights the importance of Intelligent Ultrasound to the enlarged group and will facilitate its integration into MedaPhor.”
Other than that set out above, there are no other matters that are required to be disclosed under Schedule 2 paragraph (g) of the AIM Rules in relation to the appointment of Mr. Barker.